e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Antibiotics, resistance and vaccines
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Nebulised colistimethate sodium improves quality of life in patients with bronchiectasis colonised by
pseudomonas aeruginosa
C. Haworth, D. Bilton, R. Kenyon (Cambridge, London, Chichester, United Kingdom)
Source:
Annual Congress 2013 –Antibiotics, resistance and vaccines
Session:
Antibiotics, resistance and vaccines
Session type:
Thematic Poster Session
Number:
2732
Disease area:
Airway diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Haworth, D. Bilton, R. Kenyon (Cambridge, London, Chichester, United Kingdom). Nebulised colistimethate sodium improves quality of life in patients with bronchiectasis colonised by
pseudomonas aeruginosa
. Eur Respir J 2013; 42: Suppl. 57, 2732
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
ERS statement for defining respiratory exacerbations in children and adolescents with bronchiectasis for clinical trials
ERS clinical practice guidelines on treatment of sarcoidosis
Related content which might interest you:
Assessment of health-related quality of life in patients with bronchiectasis colonized by Pseudomonas aeruginosa
Source: Virtual Congress 2021 – Bronchiectasis and pleural infection
Year: 2021
Effects of prophylactic clarithromycin administration on quality of life in non-CF bronchiectasis patients
Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections
Year: 2014
Non-CF bronchiectasis: nebulised colistimethate sodium improves symptoms and bacterial load in sputum of patients with pseudomonas aeruginosa
Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD
Year: 2008
The use of home intravenous antibiotics in adult non-CF bronchiectasis
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation
Year: 2015
Effectiveness and adherence to treatment with nebulized colistimethate sodium (Promixin®) in non-cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa (PsA)
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook
Year: 2015
The clinical impact of nebulised antibiotics in adults with bronchiectasis and chronic pseudomonas aeruginosa
Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis
Year: 2020
A single isolation of pseudomonas aeruginosa predicts poor quality of life and increased exacerbation frequency in adult bronchiectasis
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook
Year: 2015
A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic
pseudomonas aeruginosa
(PA) infection for pharmacokinetic and therapeutic equivalence
Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science
Year: 2013
Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients
Year: 2013
Influence of biofim on the bronchial microbiome in COPD patients colonized or infected by pseudomonas aeruginosa
Source: International Congress 2015 – Advances from translational research in respiratory infections
Year: 2015
Efficacy of ciprofloxacin against resistant mucoid or non-mucoid
P. aeruginosa
isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Azithromycin therapy and pseudomonas aeruginosa isolation in a non-cystic fibrosis bronchiectasis cohort
Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives
Year: 2015
Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection
Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Year: 2016
Results of Tobramycin inhalation therapy in patients with noncystic fibrosis bronchiectasis with Pseudomonas Aeruginosa colonization: Real Life Management
Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria
Year: 2020
Effectiveness of inhaled colistin by iNeb® device in non-CF bronchiectasis and chronic pseudomonas infection
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation
Year: 2015
Influence of inhaled glucocorticosteroids on course of the bronchiectasis
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Patients with no cystic fibrosis bronchiectasis colonized by
pseudomonas aeruginosa
: Role of inhaled colistin
Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections
Year: 2014
Acute exacerbations of COPD due to pseudomonas aeruginosa: Impact of antimicrobial resistance
Source: International Congress 2015 – Infection in COPD: different aspects of the host/pathogen balance
Year: 2015
A comprehensive analysis of the impact of pseudomonas aeruginosa colonisation in adult bronchiectasis
Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives
Year: 2015
The effect of nebulised colistimethate sodium on non-CF bronchiectasis with
pseudomonas aeruginosa
(preliminary report)
Source: Eur Respir J 2007; 30: Suppl. 51, 439s
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept